The aim of this article is to summaries major guidelines and review recent scientific publishing to provide valuable information for the clinician who is treating patients suffering under late-onset hypogonadism.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Introduction: As the world population grows older late-onset hypogonadism is becoming a major health problem affecting the quality of life of the older.
📊
Key Findings & Data:Introduction: As the world population grows older late-onset hypogonadism is becoming a major health problem affecting the quality of life of the older.
💡
Conclusion & Impact:The aim of this article is to summaries major guidelines and review recent scientific publishing to provide valuable information for the clinician who is treating patients suffering under late-onset hypogonadism.
Introduction: As the world population grows older late-onset hypogonadism is becoming a major health problem affecting the quality of life of the older. The aim of this article is to summaries major guidelines and review recent scientific publishing to provide valuable information for the clinician who is treating patients suffering under late-onset hypogonadism.
Özet
Dünya nüfusundaki yaşlanmaya paralel olarak geç başlayan hipogonadizm önemli bir sağlık problemi haline gelmiştir ve yaşlıların hayat kalitesini etkilemektedir. Bu yazının amacı son dönemde yapılmış bilimsel yayınların ışığında önemli uluslararası kılavuzları özetleyerek yaşlanan erkekte geç başlayan hipogonadizmli olguları tedavi etmekte olan klinisyenlere önemli bilgileri ulaştırmaktır.
GÜRKAN, L., ÇAKAN, M., KADIOĞLU, A. (2005). Investigation treatment and monitoring of late-onset hypogonadism in males. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 31 - Sayı: 3, 349–355. https://ajindex.com/articles/328422
T.C. İçişleri Bakanlığı Nüfus ve Vatandaşlık İşleri Genel Müdürlüğü: Nüfus kütüklerine kayıtlı nüfusun yaş ve cinsiyete göre dağılımı istatistiği, 2003
AACE Hyogonadisma task force: American association of clinical endociologists medical guideline for clinical practice for the evaluation of hypogonadism in adult male patients-2002 update. Endocr Pract. 8: 439-456, 2002
Nieschlag E, Behre HM: Testosterone, Cambridge University Yayınları, 1-38, 2004
Matsumoto AM: Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci. 57: 76-99, 2002
Morales A, Lunenfeld B: Investigation, treatment and monitoring of late onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 5: 74-86, 2002
Harman SM, Metter EJ, Tobin JD, et al: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 86: 724-31, 2001
Canguven O, Gurkan L, Horuz R, et al: Yaşlanan erkek semptom sorgulama formu: Türkçe geçerlilik çalışması. Androloji Bülteni. 21: 93-98, 2005
Lunenfeld B: Androgen therapy in the aging male. World J Urol 21: 292-305, 2003
Resmi ISSAM web sayfası (www.issam.ch): Serbest testosteron hesap makinesi
Laaksonen DE, Niskanen L, Punnonen K, et al: Sex hormone, inflammation, and the metabolic syndrome: A population based study. Eur J Endocrinol. 149:601, 2003
Walker BR: Steroid metabolism in metabolic syndrome X. Best Pract Res Clin Endocrinol Metab. 15: 111, 2001
Gascon F, Vale M, Martos R, et al: Sex hormone binding globulin as a marker for hyperinsulinemia and/or in-sulin resistance in obese children. Eur J Endocrinol. 143: 85, 2000
Holmag A, Bjontorp P: The effect of testosterone on insulin sensivity in male rats. Acta Physiol scand, 146: 505, 1992
Barret-Connor E, Khaw KT, Yen SS: Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol, 132: 195-201, 2002
Wang C, Swerdloff RS, Iranmanesh A, et al: transder-mal testosterone patch improves sexual function, mood, muscle strength, and body composition parameters in hy-pogonadal men. J Clin Endocrin. Metab, 85: 2839, 2000
Singh R, Artaza JN, Taylor WE, et al: Androgens sti-mulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology, 144: 5081, 2003